TITLE

United, Lung RX seek approval for inhaleable drug for PAH

PUB. DATE
July 2008
SOURCE
Cardiovascular Devices & Drugs;Jul2008, Vol. 14 Issue 7, p17
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the submission of a new drug application by United Therapeutics and its subsidiary Lung Rx in June 2008 to the U.S. Food and Drug Administration (FDA) for an inhaled formulation of treprostinil (ITRE) that can be used for the treatment of pulmonary arterial hypertension (PAH). It details the findings of a randomized trial titled "Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension" (TRIUMPH-1), which is used by United Therapeutics as basis of its application.
ACCESSION #
33516926

 

Related Articles

  • United Therapeutics's NDA for inhaled treprostinil accepted for FDA review.  // PharmaWatch: Biotechnology;Oct2008, Vol. 7 Issue 10, p7 

    The article reports that the U.S. Food and Drug Administration has accepted for review the new drug application (NDA) for inhaled treprostinil from United Therapeutics Corp. and Lung Rx in the U.S. It is noted that the NDA will be subject to a standard review period of 10 months, with a targeted...

  • A Change is Coming. Torres, Fernando; Jo Levine, Deborah // Advances in Pulmonary Hypertension;Summer2012, Vol. 11 Issue 2, p61 

    The article offers updates on the research trials that are evaluating therapies for pulmonary arterial hypertension (PAH). It notes that the primary endpoint for PAH's clinical trials has been improvement on 6-minute walk distance (6MWD). It provides information on the results of the Phase 3...

  • FDA approves United Thera's intravenous hypertension drug.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p11 

    Reports that United Therapeutics Corp. has received an approval from the U.S. Food and Drug Administration for the intravenous use of pulmonary arterial hypertension drug Remodulin. Basis of the FDA approval; Post-marketing trial conducted by United Therapeutics for the subcutaneous use of...

  • Dreamboat sinks prospects for fast approval of inhaled insulin. Kling, Jim // Nature Biotechnology;Mar2011, Vol. 29 Issue 3, p175 

    The article reports on the complete response letter issued by the U.S. Food and Drug Administration (FDA) to MannKind asking for additional data on its inhaled insulin product called Afrezza in March 2011, a move which could end the possibility of inhaled insulin. It says that the FDA requested...

  • New Type of BP Treatment Now Available.  // RN;Apr2007, Vol. 70 Issue 4, p61 

    The article reports on the approval of aliskiren, the first in a new class of drugs called direct renin inhibitors, as treatment for hypertension by the U.S. Food and Drug Administration (FDA). The effectiveness of the drug has been proven in more than 2,000 patients with mild-to-moderate...

  • CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department.  // Critical Care;2011, Vol. 15 Issue 3, p1 

    The article presents a study which aims to compare the safety and effectiveness of the U.S. Food and Drug Administration (FDA)-approved dosing of IV nicardipine with labetalol for the management of acute hypertension. It performs multicenter randomized clinical trial with 226 participants, of...

  • New combination.  // Formulary;Nov2009, Vol. 44 Issue 11, p320 

    The article focuses on the drug Valturna by Novartis AG, a combination of angiotensin receptor blocker Valsartan and direct renin inhibitor Aliskiren. The drug is approved by the U.S. Food & Drug Administration for treating hypertension. The approval of the drug was based on a clinical trial of...

  • United Therapeutics files NDA for arterial hypertension drug.  // PharmaWatch: Biotechnology;Aug2008, Vol. 7 Issue 8, p8 

    The article reports on United Therapeutics Corp.'s submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval. Their drug, called Lung Rx, is an inhaled formulation of treprostinil for the treatment of pulmonary arterial hypertension. It...

  • Extended-release calcium antagonist.  // Geriatrics;Jun96, Vol. 51 Issue 6, p18 

    Reports on the US Food and Drug Administration's approval of a new brand of extended-release diltiazem hydrogen chloride (Tiazac) for the treatment of hypertension. Mechanism of action; Recommended dosage.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics